ABSTRACT
INTRODUCTION: Several aspects of gastroesophageal reflux disease (GERD) have been studied, but the frequency of comorbidities is not yet fully understood. OBJECTIVES: To study the prevalence of GERD comorbidities in a tertiary care hospital. METHODS: We prospectively studied 670 consecutive adult patients from the outpatient department of our facility. A diagnosis was established using clinical, endoscopic and/or pHmetry-related findings. Each patient's medical file was reviewed with respect to the presence of other medical conditions and diagnoses. RESULTS: Of the 670 patients, 459 (68.6 percent) were female, and the mean age was 55.94 (17-80 years). We registered 316 patients (47.1 percent) with the erosive form of GERD and 354 patients (52.9 percent) with the non-erosive form. A total of 1,664 instances of comorbidities were recorded in 586 patients (87.5 percent), with the most common being arterial hypertension (21 percent), hypercholesterolemia (9 percent), obesity (9 percent), type II diabetes mellitus (5 percent) and depression (4 percent). Two or more comorbidities were present in 437 individuals (64.8 percent). The occurrence of comorbidities increased with age and was higher in patients with the non-erosive form of GERD. CONCLUSIONS: In a tertiary referral population, comorbidities were very common, and these may have worsened the already impaired health-related quality of life of these patients. Clinicians caring for GERD patients in this setting must be aware of the likelihood and nature of comorbid disorders and their impact on disease presentation and patient management.
Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Young Adult , Depression/epidemiology , /epidemiology , Gastroesophageal Reflux/epidemiology , Hypercholesterolemia/epidemiology , Hypertension/epidemiology , Obesity/epidemiology , Comorbidity , Gastroesophageal Reflux/classification , Hospitals, University , Prospective Studies , Young AdultABSTRACT
Os inibidores de bomba platônica (IBPs) têm elevado significado significativamente os índices de cicatrizaçäo das doenças ácido-relacionadas com mínimos eventos adversos. Pantoprazol é um IBP com propriedades farmacológicas definidas, intensa açäo anti-secretora e elevada eficácia clínica. O objetivo deste estudo foi avaliar a eficácia e a segurança de pantoprazol, 40 mg, em uma populaçäo näo selecionada, portadora de doenças ácido-relacionadas. Em estudo aberto, prospectivo, näo randomizado, ambulatorial, foram avaliados 2.222 pacientes (média etária de 44,3 anos) divididos em três grupos. Todos os pacientes receberam pantoprazol, 40 mg/dia, durante duas a oito semanas. Os índices de cicatrizaçäo da UG e DU foram 71,6 porcento e 81 porcento, respectivamente. Os índices de cicatrizaçäo das esofagites de refluxo foram de 81,2 porcento, 67,7 porcento, 50 porcento e 36,1 porcento nos graus I, II,III e IV, respectivamente, de acordo com a classificaçäo de Savary-Miller. A maioria dos eventos adversos foram leves e ocorreram em 2,5 porcento dos pacientes. Os mais freqüentemente relatados foram cefaléia, diarréia, prurido, constipaçäo e tontura. A eficácia do pantoprazol no tratamento das doenças ácido-relacionadas foi demonstrada. O bom perfil de tolerabilidade confirma a segurança do produto.(au)
Subject(s)
Humans , Adult , Middle Aged , Adolescent , Anti-Ulcer Agents , Gastroenteritis , Gastrointestinal Diseases , Duodenal Ulcer , Gastroesophageal Reflux , Stomach UlcerSubject(s)
Humans , Peptic Ulcer , Peptic Ulcer/diagnosis , Peptic Ulcer/diet therapy , Peptic Ulcer/drug therapyABSTRACT
Se efectúo la comparación entre Famotidina y Ranitidina en estudio terapéutico a corto plazo en el tratamiento de úlcera duodenal. Famotidina, 20 mg b.i.d., 40 mg b.i.d. y 40 mg nocturna cura la úlcera como la Ranitidina ((90.9%), 91.7%, 83.3% y 100% respectivamente). Una dosis simple nocturna se mostró efectiva en la prevención de la recidiva de la úlcera por un período de 48 semanas; el grado de recidiva de 38% observado con Famotidina fue estadísticamente diferente del 78% observado con placebo. Diarrea fue la molestia más común observada durante el tratamiento a corto plazo, seguido por somnolencia y cefalea. Las pocas y pequeñas alteraciones bioquimicas observadas durante el tratamiento a largo plazo (aumento de las transaminasas, fosfatasa alcalinas, glucosa, B.U.N.) no podría relacionarse directamente con el uso de la sustencia